Cefdinir: Difference between revisions
No edit summary |
No edit summary |
||
Line 11: | Line 11: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: Probably safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD | ||
**Pediatric | **Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD | ||
*Hepatic | *Hepatic dosing not defined | ||
==Contraindications== | ==Contraindications== |
Revision as of 17:44, 12 January 2016
General
- Type: Third generation cephalosporin
- Dosage Forms: 300 mg oral solid, 125/5ml susp, 250/5ml susp
- Common Trade Names: Omnicef
Adult Dosing
- 600 mg/d divided q12-24hrs for 10 days for CAP, chronic bronchitis, acute sinusitis, strep pharyngitis, cellulitis
Pediatric Dosing
- 14 mg/kg/d PO divided q12-24hrs x10 days, max of 600 mg/day
Special Populations
- Pregnancy Rating: B
- Lactation: Probably safe
- Renal Dosing
- Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
- Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
- Hepatic dosing not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- Stool discoloration which is guiac negative and returns to normal color after cessation
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
Source
- ↑ Sanford Guide to Antimicrobial Therapy 2014